Essex Bio-Tech repurchases 120,000 shares; treasury stock rises to 0.33 million units

Bulletin Express06-23

Essex Bio-Technology Limited reported a share repurchase of 120,000 ordinary shares on 23 June 2026 via on-market transactions at prices between HKD 2.63 and HKD 2.65, implying a volume-weighted average cost of HKD 2.644 per share. Total consideration amounted to approximately HKD 0.32 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) decreased from 566.80 million to 566.68 million shares, a 0.021% reduction. Treasury shares increased from 0.21 million to 0.33 million, while total issued shares remained unchanged at 567.01 million.

The repurchase was executed under the mandate approved on 26 May 2026, which permits the company to buy back up to 56.70 million shares. Cumulative purchases under this authority now stand at 0.33 million shares, equivalent to 0.06% of the outstanding shares at the mandate date, leaving capacity for a further 56.37 million shares.

In line with Hong Kong Stock Exchange regulations, Essex Bio-Tech is subject to a moratorium on new share issues or sales of treasury shares until 23 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154132495?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154132495","market":"us","top_or_hot":-1,"title":"Essex Bio-Tech repurchases 120,000 shares; treasury stock rises to 0.33 million units","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited reported a share repurchase of 120,000 ordinary shares on 23 June 2026 via on-market transactions at prices between HKD 2.63 and HKD 2.65, implying a volume-weighted average cost of HKD 2.644 per share. Total consideration amounted to approximately HKD 0.32 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) decreased from 566.80 million to 566.68 million shares, a 0.021% reduction. Treasury shares increased from 0.21 million to 0.33 million, while total issued shares remained unchanged at 567.01 million.</p>\n<p>The repurchase was executed under the mandate approved on 26 May 2026, which permits the company to buy back up to 56.70 million shares. Cumulative purchases under this authority now stand at 0.33 million shares, equivalent to 0.06% of the outstanding shares at the mandate date, leaving capacity for a further 56.37 million shares.</p>\n<p>In line with Hong Kong Stock Exchange regulations, Essex Bio-Tech is subject to a moratorium on new share issues or sales of treasury shares until 23 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Essex Bio-Tech repurchases 120,000 shares; treasury stock rises to 0.33 million units</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssex Bio-Tech repurchases 120,000 shares; treasury stock rises to 0.33 million units\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-23 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited reported a share repurchase of 120,000 ordinary shares on 23 June 2026 via on-market transactions at prices between HKD 2.63 and HKD 2.65, implying a volume-weighted average cost of HKD 2.644 per share. Total consideration amounted to approximately HKD 0.32 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) decreased from 566.80 million to 566.68 million shares, a 0.021% reduction. Treasury shares increased from 0.21 million to 0.33 million, while total issued shares remained unchanged at 567.01 million.</p>\n<p>The repurchase was executed under the mandate approved on 26 May 2026, which permits the company to buy back up to 56.70 million shares. Cumulative purchases under this authority now stand at 0.33 million shares, equivalent to 0.06% of the outstanding shares at the mandate date, leaving capacity for a further 56.37 million shares.</p>\n<p>In line with Hong Kong Stock Exchange regulations, Essex Bio-Tech is subject to a moratorium on new share issues or sales of treasury shares until 23 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1154132495","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154132495","pubTimestamp":1782205428,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited reported a share repurchase of 120,000 ordinary shares on 23 June 2026 via on-market transactions at prices between HKD 2.63 and HKD 2.65, implying a volume-weighted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"Essex Bio-Tech回购12万股；库存股增至33万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited reported a share repurchase of 120,000 ordinary shares on 23 June 2026 via on-market transactions at prices between HKD 2.63 and HKD 2.65, implying a volume-weighted average cost of HKD 2.644 per share. Total consideration amounted to approximately HKD 0.32 million.\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) decreased from 566.80 million to 566.68 million shares, a 0.021% reduction. Treasury shares increased from 0.21 million to 0.33 million, while total issued shares remained unchanged at 567.01 million.\nThe repurchase was executed under the mandate approved on 26 May 2026, which permits the company to buy back up to 56.70 million shares. Cumulative purchases under this authority now stand at 0.33 million shares, equivalent to 0.06% of the outstanding shares at the mandate date, leaving capacity for a further 56.37 million shares.\nIn line with Hong Kong Stock Exchange regulations, Essex Bio-Tech is subject to a moratorium on new share issues or sales of treasury shares until 23 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154132495","isCrawlerRequest":true}